Scientific News
-
HEALTH TECHNOLOGY ASSESSMENT | EU Implements New Rules to Offer Quicker Access to Advanced Medicines
The new rules establish an EU-wide framework for assessing health technologies by promoting collaboration and coordination among EU Member States. The goal is to help national authorities make more timely…
Read More » -
WHAT YOU NEED TO KNOW | EMA Recommends Suspension of Pfizer’s Sickle Cell Disease Drug Oxbryta
Oxbryta, which was designed to treat sickle cell disease, has been a crucial medication for patients with mild-to-moderate symptoms. Approved in the US under an accelerated process in 2019 and…
Read More » -
Stroke Risk Rises in People with Sickle Cell Disease Despite Treatment Guidelines
A new study reveals that stroke rates are continuing to rise among both adults and children living with sickle cell disease (SCD), despite established standards of care aimed at reducing…
Read More » -
How to Manage Thalassaemia During Pregnancy: Expert Advice from the BSH
A comprehensive multidisciplinary approach is essential for managing conception and pregnancy in patients with a variety of medical conditions, including obesity, diabetes, and hypertension. Thalassaemia, an inherited blood disorder that…
Read More » -
High Survival Rates for SCD Patients with Groundbreaking Transplant Approach
A bone marrow transplant strategy that avoids high-dose chemotherapy to prevent an immune reaction against donor stem cells has demonstrated high rates of event-free and overall survival in sickle cell…
Read More » -
Oxbryta Shows Promise in Reducing Cell Sickling in Pediatric SCD Patients
In a promising leap forward for pediatric sickle cell disease (SCD) treatment, the oral medication Oxbryta (voxelotor) has been shown to reduce the sickling and disintegration of red blood cells…
Read More » -
Recent Study Links Transfusion-Dependent Thalassaemia to Adverse Maternal, Neonatal Outcomes
A meta-analysis of 15 studies found that pregnant women with β-thalassaemia major and β-thalassaemia intermedia were at greater risk of heart failure, venous thromboembolism, death, and other adverse neonatal and…
Read More » -
Pain Impact and Management in Individuals With Transfusion-Dependent Thalassaemia
Over the last several decades, there has been significant progress in addressing the main symptoms and related health issues of people with transfusion-dependent thalassemia (TDT). Yet, the problem of pain…
Read More » -
Chinese Base Editing Therapy ‘Clinically Cured’ Patient with β-Thalassaemia, Researchers Say
Shanghai-based biotech company CorrectSequence Therapeutics, in collaboration with Guangxi Medical University, has achieved a significant clinical milestone by successfully treating a young patient with transfusion-dependent β-thalassaemia using their base editing…
Read More » -
CASGEVY | 1st Gene-Editing Therapy for Thalassaemia and SCD Approved in UK
Casgevy is the first medicine to be licensed that uses the innovative gene-editing tool CRISPR, for which its inventors were awarded the Nobel Prize in 2020. The therapy, developed by…
Read More »